🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  2. Sulopenem

    Iterum Therapeutics plc

    Complicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  3. Sulopenem etzadroxil/probenecid

    Iterum Therapeutics plc

    Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  4. Sulopenem-Etzadroxil/Probenecid

    Iterum Therapeutics plc

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  5. Surgery with an external ring fixator

    United Therapeutics Europe Ltd

    Severe Open Fractures of the Tibia (Shin) Bone

    phase 3 other completed

    1 trial

  6. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  7. Sutent 50 mg hard capsules, Alectinib (Alecensa), Sutent 12.5 mg hard capsules, Cotellic, Sutent 25 mg hard capsules, RO7047650, Cotellic, Alecensa 150 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, Zelboraf, Sutent 12.5 mg hard capsules, Venclexta, Venclyxto, Alecensa 150 mg hard capsules, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, RO7250726, Sutent 25 mg hard capsules, ALIMTA 500 mg powder for concentrate for solution for infusion, Sutent 50 mg hard capsules, Ze

    Hoffmann-La Roche

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  8. Suxiao Jiuxin Pill

    The First People's Hospital of Lianyungang

    Acute Mountain Sickness

    phase 3 small molecule active

    1 trial

  9. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  10. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  11. Systematic oral health education

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor of Head and/or Neck

    phase 3 other completed

    1 trial

  12. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  13. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  14. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  15. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  16. TAK-625

    Takeda

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  17. TAK-667

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  18. TAK-672

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  19. TAK-743 300 mg

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  20. TAK-816

    Takeda

    Healthy Volunteers

    phase 3 mab completed

    1 trial

  21. TARA-002

    Protara Therapeutics

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    1 trial

  22. TASIMELTEON, HETLIOZ 20 mg hard capsules

    Lacuna Pharma Pty Ltd

    Non-24 Hour Sleep-Wake Disorder

    phase 3 small molecule active

    1 trial

  23. TAXOL 6 mg/ml, concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  24. TBP-PI-HBr

    Spero Therapeutics

    Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources